We’re pioneering a new approach to LBCL treatment with our groundbreaking ALPHA3 trial that aims to identify and treat patients as part of the 1L regimen, potentially transforming the standard of care. $ALLO?#CART #celltherapy #immunotherapy Learn About the ALPHA3 Trial’s Groundbreaking Design:?Allogene.com/Pipeline
关于我们
Allogene Therapeutics, with headquarters in South San Francisco, is a clinical-stage biotechnology company pioneering the development of allogeneic chimeric antigen receptor T cell (AlloCAR T?) products for cancer and autoimmune disease. For additional information on our guidelines, please visit www.allogene.com/news-center#community-guidelines Please be aware that the FBI recently issued a warning about an increased number of fake job postings for remote work employment that target applicants' personally identifiable information. All approved Allogene Therapeutics positions are accessible via the Allogene Careers page at www.allogene.com/careers.
- 网站
-
www.allogene.com
Allogene Therapeutics的外部链接
- 所属行业
- 生物技术
- 规模
- 201-500 人
- 总部
- South San Francisco，California
- 类型
- 上市公司
- 创立
- 2017
- 领域
- oncology、cancer、biotechnology、immunotherapy、CAR T和autoimmune
地点
Allogene Therapeutics员工
动态
-
Investigational AlloCAR?T? products are designed to overcome limitations of today’s autologous therapies and deliver these transformative treatments?to more patients where they seek care. $ALLO #CART #celltherapy #immunotherapy Explore the Potential of Expanded CAR T Access:?Allogene.com/Pipeline?
-
Pleased to report our Q4 and full year 2024 corporate update and business highlights. View our Q4 and Full Year 2024 update: https://lnkd.in/g4uCrE7Q
-
In case you missed it. Check out our webcast from the TD Cowen 45th Annual Health Care Conference. You can access the webcast here:?https://lnkd.in/eBV4zW9?#Biotech #CART #celltherapy #immuotherapy
-
-
Join us for our Q4 and full year 2024 conference call on Thursday, March 13 at 2:00 p.m. PT / 5:00 p.m. ET. A webcast will be available on the investor section of?our website.?https://lnkd.in/gepuZBj3 $ALLO #Biotech #CART #celltherapy #immuotherapy?
-
Join us for our Q4 and full year 2024 conference call on March 13th at 2:00 p.m. PT / 5:00 p.m. ET. A webcast will be available on the investor section of our website. Tune in for our quarterly call: https://lnkd.in/gepuZBj3
-
We are looking forward to participating in the upcoming?TD Securities Cowen 45th?Annual Health Care Conference. Tune in to our fireside chat to hear why we believe in the future of AlloCAR T? products. Webcasts available in the IR section of our website. #CART Webcasts available on the IR Website: https://lnkd.in/gfptUCzq
-
-
We’re excited to announce the expansion of our strategic collaboration with?Foresight Diagnostics?to enable the development of their investigational minimal residual disease (MRD) assay as a companion diagnostic in the EU, UK, Canada, and Australia in support of the clinical development of our allogeneic CAR T, cema-cel. This expanded partnership brings us closer to unlocking the full potential of CAR T products. Learn more about ALPHA3: https://lnkd.in/gHZW2rkA
-
Learn how our experience and differentiated science is enabling us to design and develop a CAR T 2.0 product for autoimmune disease that is scalable and could eliminate or?reduce lymphodepletion to meet the unique needs of patients. $ALLO #CART #celltherapy #immunotherapy Uncover the Potential of ALLO-329:?Allogene.com/Pipeline?
-
At Allogene, we’ve rewritten the CAR T playbook. Our approach to development and trial design has the potential to deliver ‘off-the-shelf’ CAR T products that dowhat autologous CAR T therapies cannot. $ALLO #CART #celltherapy #immunotherapy Explore Innovation at Allogene:?Allogene.com/Science?
-